Will Schering-Plough’s Vytorin Headache Prove Contagious?
Executive Summary
The full impact of Schering-Plough's deepening woes after a scientific panel's negative analysis of the Vytorin ENHANCE trial will not be known for a while, and some analysts predict there could be repercussions beyond the company and its joint venture with Merck, a deal centered on the anti-cholesterol drug, which combines the statin Zocor (simvastatin) withZetia (ezetimibe)
You may also be interested in...
Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles
Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others
Merck Commercial Pilot Set To Fly Nationwide
Merck is rolling out a new commercial model, including a realigned sales organization, nationwide following a successful pilot program, Global Human Health President Kenneth Frazier said
Schering Looks Overseas, Under Couch To Sustain Growth As Vytorin Stumbles
Schering-Plough's strategy for reducing its elevated cholesterol worries depends on the firm capitalizing on one industry trend while bucking a few others